Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion.

Conference item

Between January 1985 and March 1992, 48 patients with chronic phase CML underwent BMT from volunteer unrelated donors (MUD) serologically identical at HLA-A, B and DR loci. 19 patients received donor marrow ex vivo T-cell depleted (EX-TCD) with Campath monoclonal antibodies. 29 patients received unmanipulated donor marrow with CsA/MTX GVHD prophylaxis; 28 received additional intravenous antilymphocyte therapy from day +1 to +5 (IN-TCD). Overall 26 patients survive at median follow up of 362 days; actuarial survival at 3 years is 50%. 3 patients have sustained haematological relapse; actuarial leukaemia-free survival is 38%. There is no difference in overall survival between the EX-TCD and IN-TCD groups, but primary graft failure (n = 4) occurred only in the EX-TCD group, while GVHD (grade II or greater) occurred more frequently in the IN-TCD group (61% vs. 29%, p = 0.084). The optimum method for GVHD prophylaxis in MUD BMT remains uncertain.

Authors: Cullis, J; Szydlo, R; Cross, N; Marks, D; Schwarer, A

• Publication status: Published
• Host title: Bone marrow transplantation
• Volume: 11 Suppl 1
• Pages: 107-111
• Publication date: 1993-01-01
• Event location: ENGLAND
• EISSN: 1476-5365
• ISSN: 0268-3369
• Keywords: Lymphocyte Depletion; Male; DNA; Retrospective Studies; Transplantation, Homologous; Middle Aged; HLA-DR Antigens; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Great Britain; Adult; HLA-A Antigens; Polymerase Chain Reaction; Tissue Donors; Child; Adolescent; Bone Marrow Transplantation; HLA-B Antigens; Humans; T-Lymphocytes; Female